bioAffinity Technologies

Call Directions Website

bioAffinity Technologies Addressing the need for noninvasive diagnosis of early-stage cancer and targeted cancer treatment. www.cypathlung.com

Our flagship product, CyPath® Lung, is a noninvasive early lung cancer diagnostic.

10/14/2026

Not every indeterminate pulmonary nodule leads directly to biopsy.

In this physician’s experience, a CyPath® Lung result supported a decision to monitor the patient, with follow-up CT later showing that the nodule remained stable. The case illustrates how additional diagnostic information can help inform decisions about what comes next.

Learn more: https://www.cypathlung.com/

bioAffinity Technologies (Nasdaq: BIAF) is presenting new research at on the development of sputum-based tests to meas...
10/13/2026

bioAffinity Technologies (Nasdaq: BIAF) is presenting new research at on the development of sputum-based tests to measure lung inflammation in asthma and COPD.

The research examines the ability to measure multiple cellular and soluble protein biomarkers in sputum, including targets associated with approved and investigational biologic therapies. The approach builds on the flow cytometry + AI platform used in CyPath® Lung and explores how a more detailed picture of lung inflammation could identify biologic therapies specific to individual patients for a precision medicine approach.

Read the announcement: https://bit.ly/4yPC6eW

We join the world in wishing Pope Leo XIV all the best for his health and well-being.The recent news of the Pope's lung ...
10/12/2026

We join the world in wishing Pope Leo XIV all the best for his health and well-being.

The recent news of the Pope's lung nodule highlights the importance of lung cancer screening and early diagnosis.

At bioAffinity Technologies, we are working every day to advance noninvasive healthcare solutions for the early detection and monitoring of lung disease to provide better outcomes for patients.

Finding lung cancer early can save lives. But a positive LDCT result does not necessarily mean cancer. In the National L...
10/12/2026

Finding lung cancer early can save lives. But a positive LDCT result does not necessarily mean cancer. In the National Lung Screening Trial, LDCT had a positive predictive value of just 3.8%, meaning most people with a positive result did not ultimately have lung cancer.

That uncertainty can lead to additional testing, anxiety, cost and potentially invasive procedures.

CyPath® Lung is designed to provide additional information after a positive LDCT through a noninvasive sputum test. Its binary result – either likely or unlikely malignancy – can help physicians make more informed decisions about appropriate follow-up.

Learn more: https://www.cypathlung.com/

This week brought another opportunity to connect directly with the VA healthcare community.VA Pulmonary Sales Executive ...
10/09/2026

This week brought another opportunity to connect directly with the VA healthcare community.

VA Pulmonary Sales Executive Matt McCumber represented bioAffinity Technologies at the Government Expo at the San Diego VAMC, where he connected with clinicians and federal healthcare decision-makers and showcased CyPath® Lung.

These conversations help build awareness of CyPath® Lung across federal healthcare and create opportunities to learn more about the needs of the clinicians and patients we aim to serve.

bioAffinity Technologies (Nasdaq: BIAF) has received a Notice of Allowance from the Japan Patent Office for its method o...
10/08/2026

bioAffinity Technologies (Nasdaq: BIAF) has received a Notice of Allowance from the Japan Patent Office for its method of predicting the likelihood of lung cancer powered by CyPath® Lung, the company's noninvasive test for early-stage lung cancer.

Once issued, it will be the first patent awarded in Japan for CyPath® Lung driven by an AI-built algorithm and the fifth patent protecting the test in Asia, including China and Hong Kong. It joins a portfolio of 22 awarded U.S. and foreign patents and 36 pending applications.

CyPath® Lung uses flow cytometry and artificial intelligence with at-home sample collection to assess indeterminate pulmonary nodules in patients at high risk for lung cancer.

Read the announcement: https://bit.ly/4dXM8SE

CyPath® Lung is seeing growth from both new and existing physician users.Through the third quarter of 2026, the number o...
10/08/2026

CyPath® Lung is seeing growth from both new and existing physician users.

Through the third quarter of 2026, the number of physician offices using CyPath® Lung increased by nearly 90%. At the same time, physicians who ordered CyPath® Lung in 2025 increased their utilization by nearly 50%.

Together, these trends contributed to more than 100% growth in CyPath® Lung sales through Q3 2026 and reflect continued expansion of the test in clinical practice.

ICYMI, read the latest update: https://bit.ly/4766Ko0

bioAffinity Technologies (Nasdaq: BIAF) reported more than 100% growth in CyPath® Lung sales through the third quarter o...
10/06/2026

bioAffinity Technologies (Nasdaq: BIAF) reported more than 100% growth in CyPath® Lung sales through the third quarter of 2026, reflecting continued growth in clinical adoption of the noninvasive lung cancer test.

The number of ordering physicians increased 89% compared with Q3 2025, while physicians who had already ordered CyPath® Lung increased utilization by 48%.

Read the release: https://bwnews.pr/4huWlbz

10/05/2026

A high-risk patient was referred for a suspicious lesion in the right lung, but after his symptoms improved, he preferred to monitor the nodule rather than proceed with a biopsy.

But after a positive CyPath® Lung result, he chose to undergo a biopsy, which confirmed Stage 1A lung cancer.

can help physicians assess malignancy risk and support decision-making when determining whether a pulmonary nodule warrants further evaluation. https://www.cypathlung.com/

10/02/2026

Interventional pulmonology practices can help a community find lung cancer earlier by making sure high-risk patients get screened, lung nodules are evaluated promptly, and patients receive the right level of follow-up.

For high-volume interventional pulmonology practices like Dr. Guda's, CyPath® Lung is a valuable tool that can help clinicians identify which patients are appropriate for "watchful waiting" and which should move forward with more invasive evaluation, including biopsy.

More information. Better-informed decisions.

Learn more: https://www.cypathlung.com/

Address

3300 Nacogdoches Road Ste 216
San Antonio, TX
78217

Telephone

+12106985334

Website

Alerts

Be the first to know and let us send you an email when bioAffinity Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category